Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: A hoosier oncology group trial

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 935-939

  Bandealy, Malik T ^a   Gonin, René ^a   Loehrer, Patrick J ^a   Monaco, Frank ^b   Einhorn, Lawrence H ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b Hoosier Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LEVAMISOLE;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; LEVAMISOLE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0031892995     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
2. Heidelberger, C., Chaudhari, N. K., Danneberg, P., et al. Fluorinated pyrimidine. A new class of tumor-inhibitory compounds. Nature (Lond.), 179: 663-666, 1957.
3. Grem, J. L., Hoth, D. F., Hamilton, J. M., et al. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat. Rep., 71: 1249-1264, 1987.
4. Einhorn, L. H. Improvements in 5-FU chemotherapy? J. Clin. Oncol., 7: 1377-1379, 1989.
5. Nobile, M. T., Rosso, R., Sertoli, M. R., et al. Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur. J. Cancer, 28A: 1823-1827, 1992.
6. Petrelli, N., Douglass, H. O., Herrera, L., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase in trial. J. Clin. Oncol., 7: 1419-1426, 1989.
7. Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., and Mittelman, A. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol., 5: 1559-1565, 1987.
8. Valone, F. H., Friedman, M. A., Wittlinger, P. S., Drakes, T., Eisenberg, P. D., Malec, M., Hannigan, J. F., and Brown, B. W., Jr. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J. Clin. Oncol., 7: 1427-1436, 1989.
9. Di Costanzo, F., Bartolucci, R., Calabresi, F., Sofra, M., Marzola, M., Belsanti, V., Boni, C., and Bacchi, M., Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann. Oncol., 3: 371-376, 1992.
10. Labianca, R., Pancera, G., Aitini, E., et al. Folinic acid + 5-fluorouracil versus equidose 5-FU in advanced colorectal cancer. Phase III study of "GISCAD" (Italian Group for the Study of Digestive Tract Cancer). Ann. Oncol., 2: 673-679, 1991.
11. Poon, M. A., O'Connell, M. J., Moertel, C. G., et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 7: 1407-1418, 1989.
12. Doroshow, J. H., Multhauf, P., Leong, L., et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J. Clin. Oncol., 8: 491-501, 1990.
13. Erlichman, C., Fine, S., Wong, A., and Elhakim, T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 6: 469-475, 1988.
14. Martoni, A., Cricca, A., Guaraldi, M., Covizzi, M., Farris, A., and Pannuti, F. Weekly regimen of 5-FU versus 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer. Anticancer Res., 12: 607-612, 1992.
15. Petrioli, R., Lorenzi, M., Aquino, A., et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur. J. Cancer, 31A: 2105-2108, 1995.
16. Steinke, B., Gunther, E., Hirschmann, W. D., Sondern, W., Koniczek, K. H., Wander, H. E., Natt, F., Wagner, T., Hinrichs, H. F., and Werdier, D. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer: preliminary results of a randomized trial. Semin. Oncol., 19: 141-147, 1992.
17. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
18. Loehrer, P. J., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R., Stephens, D., Woodburn, R., and Meyers, S. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group Trial. J. Clin. Oncol., 6: 642-648, 1988.
19. Labianca, R., Pancera, G., Cesana, B., et al. Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur. J. Cancer Clin. Oncol., 24: 1579-1581, 1988.
20. Buroker, T. R., Moertel, C. G., Fleming, T. R., et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J. Clin. Oncol., 3: 1624-1631, 1985.
21. Verhaegen, H., DeCree, J., DeCook, W., et al. Levamisole therapy in patients with colorectal cancer. In: W. D. Terry and S. A. Rosenberg (eds.), Immunotherapy of Human Cancer, pp. 225-229. New York: Elsevier North Holland, 1982.
22. Chlebowski, R. T., Nystrom, S., Reynolds, R., et al. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study group trial. Oncology, 45: 141-143, 1988.
23. Arnaud, J. P., Buyse, M., Nordlinger, B., Martin, F., Pector, J. C., Zeitoun, P., Adloff, A., and Duez, N. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br. J. Surg., 76: 284-289, 1989.
24. Laurie, J. H., Moertel, C. G., Fleming, T. R., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol., 7: 1447-1456, 1989.
25. Moertel, C. G., Fleming, T. R., Macdonald, J. S., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
26. Borden, E. C., Davis, T. E., Crowley, J. J., et al. Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma. In: W. D. Terry and S. A. Rosenberg (eds.), Immunotherapy of Human Cancer, pp. 231-235. New York: Elsevier North Holland, 1982.
27. Mansour, E. G., Cnaan, A., Davis, T., et al. Combined modality therapy following resection of colorectal carcinoma in patients with non-measurable intra-abdominal metastases. An ECOG study 3282. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 9: 107, 1990.
28. Zar, J. H. Biostatistical Analysis (2nd ed.), pp. 138-146, 290-395. Englewood Cliffs, NJ: Prentice-Hall, 1984.
29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
30. Armitage, P., and Berry, G. Statistical Methods in Medical Research (2nd ed.), pp. 427-433. Oxford: Blackwell Scientific Publications, 1987.
31. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
32. Longrée, L., Focan, C., Bury, J., Beauduin, M., Brohee, D., Duvivier, A., Lecomte, M., Markiewicz, S., Vindevoghel, A., and Weerts, J. Levamisole adds granulocyte toxicity to 5-FU based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report. Anticancer Res., 15: 1561-1564, 1995.
33. Mayer, R. J. Does adjuvant therapy work in colon cancer? N. Engl. J. Med., 322: 399-401, 1990.
34. Wolmark, N., Rockett, H., Mamounas, E. P., et al. The relative efficacy of 5-FU + leucovorin, 5-FU + levamisole, and 5-FU + leucovorin + levamisole in patients with Duke's B and C carcinoma of the colon: first report of NSABP C-04. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 205, 1996.
35. O'Connell, M. J., Laurie, J. A., Shepherd, L., et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 209, 1996.
36. Haller, D. G., Catalona, P. J., MacDonald, J. S., and Mayer, R. J. Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer: four year results of INT-0089. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 265, 1997.